Related Experiment Video
Updated: Sep 18, 2025

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
[Phage therapy for multidrug-resistant Acinetobacter baumannii]
1Department of Medical Laboratory Science, Changzhi Medical College, Changzhi 046000, Shanxi, China.
Abstract:
Acinetobacter baumannii is a Gram-negative opportunistic pathogen widely distributed in hospital settings. It can survive for a long time and cause a variety of infections, including pneumonia, septicemia, urinary tract infections, and meningitis. The bacterium demonstrates extensive resistance, particularly to critical antibiotics like carbapenems and polymyxins, posing a serious threat to the recovery of severely ill patients. Carbapenem-resistant A. baumannii has been designated as a pathogen of critical priority on the World Health Organization (WHO) Bacterial Pathogen Priority List, requiring urgent development of new therapeutic agents. Phages, as a novel biological control approach, exhibit substantial potential in combating A. baumannii infections due to their specific ability to infect and lyse bacteria. This review highlights the application and potential of phages and phage-derived enzymes against multidrug-resistant A. baumannii, considering the epidemiological trends of A. baumannii in China, with the aim of providing innovative insights and strategies for phage therapy of drug-resistant bacterial infections.
Insights
Bacteriophage therapy shows promise against multidrug-resistant Acinetobacter baumannii, a critical hospital pathogen. This review explores phage applications and strategies for combating these difficult-to-treat infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Bacteriology
Background:
- Acinetobacter baumannii is a Gram-negative opportunistic pathogen causing severe hospital-acquired infections.
- It exhibits extensive resistance to critical antibiotics, including carbapenems and polymyxins.
- Carbapenem-resistant A. baumannii is a WHO priority pathogen, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review the application and potential of phages and phage-derived enzymes against multidrug-resistant A. baumannii.
- To consider epidemiological trends of A. baumannii in China.
- To provide insights for phage therapy of drug-resistant bacterial infections.
Main Methods:
- Literature review of phage therapy applications.
- Analysis of epidemiological data for A. baumannii in China.
- Evaluation of phage and phage-derived enzymes against resistant strains.
Main Results:
- Phages demonstrate specific lytic activity against A. baumannii.
- Phage therapy offers a viable alternative to antibiotics for resistant strains.
- Epidemiological data highlights the prevalence and threat of A. baumannii in China.
Conclusions:
- Phage therapy presents a promising approach to combatting multidrug-resistant A. baumannii.
- Further research and clinical application of phages are warranted.
- Phage-based strategies can contribute to managing critical bacterial infections.
Related Concept Videos
Lytic Cycle of Bacteriophages
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Gene Regulation in Microbial Communities: Quorum Sensing
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

